Related Experiment Videos
Cutaneous drug reactions. An attempt to quantitative estimation
1Department of Dermatology, University of Gothenburg, Sahlgren's Hospital, Sweden.
Archives of Dermatological Research
|January 1, 1992
Summary
This study investigated drug risks for cutaneous drug reactions (CDR) in 440 patients. Gold compounds, trimethoprim, cephalosporins, and penicillins showed the highest CDR risk, with macular and mucalopapular eruptions being most common.
Area of Science:
- Dermatology
- Pharmacology
- Clinical Research
Background:
- Cutaneous drug reactions (CDR) are common adverse events.
- Accurate risk assessment requires accounting for drug usage frequency.
- Previous studies like the Boston Collaborative Drug Surveillance Program provide valuable data.
Purpose of the Study:
- To prospectively identify drugs associated with a high risk of cutaneous drug reactions.
- To quantify CDR risk by correcting for drug usage frequency.
- To compare findings with existing drug surveillance data.
Main Methods:
- Prospective study conducted over 4 years at Sahlgren Hospital, Gothenburg.
- Inclusion of 440 patients with suspected cutaneous drug reactions.
- Calculation of CDR risk by dividing drug occurrence frequency by the number of sold defined daily doses (SDDD).
Main Results:
- Gold compounds, trimethoprim (with/without sulfonamides), cephalosporins, and penicillins demonstrated the highest CDR risk.
- Macular and mucalopapular eruptions were the most frequent CDR types observed.
- Urticaria and cutaneous vasculitis were also common manifestations.
Conclusions:
- Specific drug classes, including gold compounds and certain antibiotics, pose a significant risk for CDR.
- The study's findings align with previous drug surveillance program results.
- Risk-adjusted analysis is crucial for understanding the true incidence of drug-induced skin reactions.